Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- India Scales Up HPV Vaccination, Screening in Cervical Cancer Elimination Push: Health Minister J.P. Nadda
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
Chief Non-Staff Specialist Oncologist of Russia proposes to cancel the third phase of clinical trials of abroad registered drugs
- By Newsdesk
- Russia
- Jun 26, 2023
Andrey Kaprin, the General Director of the National Medical Research Center for Radiology and Chief Non-Staff Specialist Oncologist of the Ministry of Health of Russia, discussed the possibility of exempting phase III clinical trials for drugs that are already registered abroad during a discussion at the Federation Council. He provided an example of individuals suffering from synovitis who often rely on non-steroidal anti-inflammatory drugs (NSAIDs) for an extended period to effectively alleviate joint pain. Although the drug is ready for use, it still requires a third phase of clinical trials. However, the Ministry of Health is not authorized to finance the third phase and can only fund the first and second phases through the state order.
Kaprin also mentioned that the primary focus of the third stage of research is commercialization. While the trial typically takes three to four years to complete, the drug could potentially be administered to patients during this period, providing potential benefits.
In May, the Russian Association of Oncologists reported that the availability of drugs for cancer patients remained unaffected by any issues. Kaprin emphasized that many drugs have been replaced by their generic counterparts, which may differ in certain aspects.